PCVXVaxcyte, Inc.

$9B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$19M

Net Income

-$21M

EPS (Diluted)

$-0.41

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$393M

Total Liabilities

$47M

Stockholders' Equity

$346M

Cash & Equivalents

$386M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$19M	-$16M	-22.8%
Net Income	-$21M	-$18M	-16.4%

PCVX Q4 2020 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena